ArticlePakistan journal of medical sciences2026
Efficacy of drug-eluting bead transarterial chemoembolization in patients with intermediate to advanced hepatocellular carcinoma and its effects on serum γ-glutamyl transferase, calcium-phosphorus metabolism, and hepatic reserve function.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical efficacy of drug-eluting bead transarterial chemoembolization(DEB-TACE) in patients with intermediate to advanced hepatocellular carcinoma(HCC) and its effects on serum γ-glutamyltransferase (GGT), calcium-phosphorus metabolism, and hepatic reserve. Methodology: A retrospective analysis was conducted on the clinical data of 120 patients with intermediate to advanced HCC treated at Affiliated Hospital of Hebei University between January 2020 to December 2024. Based on the interventional approach, patients were divided into a control group( Results: The disease control rate was significantly higher in the observation group than in the control group( Conclusion: DEB-TACE demonstrates multidimensional clinical benefits in the treatment of intermediate and advanced HCC. It offers superior disease control, effectively reduces serum tumor markers, ameliorates calcium-phosphorus metabolic disturbances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.